

Method optimization and scale-up of the purification of recombinant bovine carbonic anhydrase with IMAC Sepharose 6 Fast Flow

Intellectual Property Notice: The Biopharma business of GE Healthcare was acquired by Danaher on 31 March 2020 and now operates under the Cytiva[™] brand. Certain collateral materials (such as application notes, scientific posters, and white papers) were created prior to the Danaher acquisition and contain various GE owned trademarks and font designs. In order to maintain the familiarity of those materials for long-serving customers and to preserve the integrity of those scientific documents, those GE owned trademarks and font designs remain in place, it being specifically acknowledged by Danaher and the Cytiva business that GE owns such GE trademarks and font designs.

cytiva.com

GE and the GE Monogram are trademarks of General Electric Company.

Other trademarks listed as being owned by General Electric Company contained in materials that pre-date the Danaher acquisition and relate to products within Cytiva's portfolio are now trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.

Cytiva and the Drop logo are trademarks of Global Life Sciences IP Holdco LLC or an affiliate. All other third-party trademarks are the property of their respective owners. © 2020 Cytiva

All goods and services are sold subject to the terms and conditions of sale of the supplying company operating within the Cytiva business. A copy of those terms and conditions is available on request. Contact your local Cytiva representative for the most current information.

For local office contact information, visit cytiva.com/contact

CY14390-11Jun20-AN

Application Note 28-4044-80 AA

Method optimization and scale-up of the purification of recombinant bovine carbonic anhydrase with IMAC Sepharose 6 Fast Flow

Abstract

This application note describes the purification of recombinant bovine carbonic anhydrase II (r-BCA) using IMAC Sepharose™ 6 Fast Flow in the capture step. Immobilized metal ion affinity chromatography (IMAC) is an excellent purification technique for proteins with exposed histidine residues that have affinity for metal ions. r-BCA is an example of such a protein.

IMAC Sepharose 6 Fast Flow is an IMAC medium that the user charges with the metal ion of choice. The medium provides high protein binding capacity for purification of histidine-tagged proteins as well as untagged proteins. As member of the BioProcess™ media family, IMAC Sepharose 6 Fast Flow meets the demands of industrial biotechnology with security of supply, comprehensive regulatory support, and necessary support for process applications.

This study presents results from method optimization and scale-up work. The method was optimized at laboratory scale with HiTrap™ IMAC FF 1 ml column to determine the best choice of metal ion and the preferred elution conditions. Once these parameters were established, they were then used in a scale-up study using HiTrap IMAC FF 5 ml column and HiPrep™ IMAC FF 16/10 20 ml column.

With the r-BCA protein, high purity was obtained with all three metal ions tested (Cu²⁺, Ni²⁺, and Zn²⁺). Binding strength in the order $Zn^{2+} = Ni^{2+} > Cu^{2+}$ was observed. Due to its low toxicity, Zn^{2+} is often the most preferable metal ion to use in process scale, and thus it was chosen for the additional experiments described in this application note.



Fig 1. Purification of recombinant bovine carbonic anhydrase II (r-BCA)

Results also showed good recovery and purity in the elution methods tested (imidazole and pH). However, pH elution was chosen for the scale-up studies since it is less expensive than imidazole elution and therefore preferable for work at process-scale.

The scale-up studies gave very good yields with both HiTrap IMAC FF and HiPrep IMAC FF 16/10 columns. No significant change in recovery and purity was seen between the different scales. Moreover, there was only a very low level of leakage of metal ions from the columns, and leaked ions were easily removed by a desalting step.





Introduction

Since its introduction in 1975, IMAC has become one of the most widely used biochemical separation methods for purifying a broad range of biomolecules at the capture, intermediate, or polishing steps.

IMAC is based on the specific interaction between immobilized transitional metal ions and some key amino acid residues exposed on the surface of proteins (mainly histidine and to a lesser extent cysteine and tryptophan). The strength of interaction is primarily dependent on the type, number, and spatial distribution of the relevant amino acid residues and the nature of the immobilized metal ions. The presence of several adjacent histidine residues in histidine-tagged proteins is the most important parameter responsible for the high affinity between immobilized metal ions and such recombinant proteins in crude extracts of *Escherichia coli* or other biological sources. Even denatured proteins that are produced in *E. coli* as inclusion bodies have been purified and refolded using this technology.

Purification of (histidine)₆-tagged proteins is at present a widely used technique in laboratories throughout the world. It is also increasingly used for large-scale purification of native, untagged proteins or their recombinant counterparts. IMAC is already being used in several approved biopharmaceutical processes.

In many instances it is not always possible to predict which metal ion will be the most appropriate for purifying a protein, and there are often other factors to consider when making the choice. For these reasons, uncharged IMAC Sepharose 6 Fast Flow provides flexibility in planning, testing, and optimizing a purification scheme. The medium also has the added advantage of low metal ion leakage and different adsorption specificity compared with other commercial IMAC media.

Key features of IMAC Sepharose 6 Fast Flow include:

- possible to charge with various metal ions for optimized selectivity
- high protein binding capacity
- BioProcess medium designed to match manufacturing needs for security of supply, robust performance, and regulatory support
- available in the convenient and time-saving prepacked HiPrep and HiTrap format

In some cases involving untagged proteins and especially in *E. coli* applications, IMAC may not be applicable for use in the capture step, since unwanted host cell proteins can bind to the medium and displace the target protein. In contrast, the use of IMAC in the intermediate purification steps often gives excellent purity. This study, however, shows the possibility of using IMAC Sepharose 6 Fast Flow in the capture step in the purification of r-BCA from *E. coli* with good results. The objective of the work was to demonstrate method optimization for purifying r-BCA, focusing on choice of metal ion and elution conditions, and then scale up the method to purify larger amounts of the protein.

Materials and Methods

Unless otherwise stated, all chromatographic media and systems were obtained from GE Healthcare (Uppsala, Sweden). HiTrap IMAC FF 1 ml and 5 ml columns and HiPrep IMAC FF 16/10 20 ml columns were used. The chemicals used were of analytical or reagent grade. All experiments were performed at room temperature (22°C) on a calibrated ÄKTAexplorer™ 100 system with a 0.2 cm UV cell, controlled by UNICORN™ software.

Preparation of starting material

The molecular weight of r-BCA is M_r 30 000 Da. The enzyme catalyzes esterase activity, which can be measured and followed in a purification process. The active site functions with a single zinc ion that is essential for the catalysis. The amount of protein in solutions containing r-BCA was estimated by absorbance at 280 nm using the factor: A^{1 mg/ml} at 280 nm = 1.8.

E. coli cell paste containing r-BCA was homogenized in elution buffer by sonication. The crude extract was then clarified by centrifugation at 19 000 rpm for 35 min at 5°C. The clarified crude extract was adjusted to pH 7.7 and filtered through a 0.45 μ m filter and stored at –20°C until further use.

The extract was thawed and re-filtered through a 0.2 μ m filter before purification. The level of expression of the target protein was estimated at 30 mg/g of wet cell paste and 5.2 mg/ml in the clarified extract. The binding capacity of IMAC Sepharose 6 Fast Flow for r-BCA was determined to be 17 mg/ml Zn²⁺-charged medium, by frontal analysis of the *E. coli* extract.

Choice of metal ion and elution conditions

Initially, three metal ions (Cu²⁺, Ni²⁺, and Zn²⁺) and two elution methods (imidazole and pH) were tested to establish optimal conditions for purifying r-BCA from analytical to process-scale operations. HiTrap IMAC FF 1 ml columns were used to establish the conditions.

Scale-up

When the purification had been optimized, the process was scaled up using Zn²⁺ as the immobilized metal ion and pH step elution to elute the target protein. The scale-up was verified at two scales (HiTrap IMAC FF 5 ml and HiPrep IMAC FF 16/10 20 ml) keeping the residence time constant while bed height and flow velocity were increased.

Leakage of zinc ions

The amount of zinc in the applied sample, flowthrough fraction, and bound fraction (after elution from the column) was determined by atomic absorption spectrophotometry. Since carbonic anhydrase already contains one mol of zinc per mol of protein, the amount of zinc that leaked from the column is the difference between the zinc content in the sample and the eluted fractions. Desalting (HiPrep 26/10 Desalting) was also performed to remove residual zinc ions from the target protein solutions.

Results and discussion

The selection of a suitable metal ion, protein, and chromatographic operating conditions for this application work was made on the basis of well-planned and executed screening experiments, as described in the following sections, with reference to Figures 2 and 3.

Selection of metal ion and elution conditions

The elution profiles after purification of *E. coli* extract on HiTrap IMAC FF 1 ml charged with Zn^{2+} , Ni^{2+} , or Cu^{2+} ions are shown in Figure 2. The results show that r-BCA is bound to the same extent on immobilized Zn^{2+} and Ni^{2+} but distinctly less on immobilized Cu^{2+} . Given these results and the fact that Zn^{2+} is less toxic and more environmentally friendly than either Ni^{2+} or Cu^{2+} , immobilized Zn^{2+} was selected as the metal ion of choice for this application. Lower toxicity and good binding charateristics make Zn^{2+} particularly attractive for process-scale operations.

Figure 3 shows that elution of bound proteins with a linear or stepwise pH gradient (which protonates the amino acid side chains involved in binding) is as effective as elution with imidazole (which is a competitive elution agent).



Fig 2. Overlay chromatograms from purification of 5 ml of extract of r-BCA on a 1 ml IMAC Sepharose 6 Fast Flow column charged with Cu^{2+} , Ni^{2+} , or Zn^{2+} . Based on the elution positions of the bound proteins, the affinity of the metal ions for r-BCA was in the order $Zn^{2+} = Ni^{2+} > Cu^{2+}$.

pH gradient elution





pH step elution





Fig 3. Purification of r-BCA on a 1 ml IMAC Sepharose 6 Fast Flow column charged with Zn²⁺. The bound fraction was eluted with a linear (A) or stepwise (B) pH gradient. The purity was analyzed by non-reduced SDS-PAGE on PhastGel™ Gradient 8-25 (C). The gel was stained with Coomassie™.



Fig 4. Scaling up the purification of r-BCA from 1 ml to 5 ml to 20 ml columns of IMAC Sepharose 6 Fast Flow charged with Zn^{2+} ions.

Considering the much lower costs of buffer salts compared with imidazole, elution of bound proteins by lowering the pH is the most preferred elution method for process-scale operations. Therefore pH elution was chosen for the scaleup studies.

Scale-up

The results show trouble free scale-up of the purification from 1 ml to 5 ml to 20 ml columns with yields of 12, 56, and 235 mg of r-BCA respectively. Figure 4 shows the chromatograms and Figure 5 shows the SDS-PAGE analysis of the flowthrough fractions and eluted pools from the different runs. Table 1 compares yields and recoveries, showing the scalability of the application.

More than 90% of the protein was recovered in each instance at a load of 74% of binding capacity (i.e. 17 mg/ml medium). The recovery of applied activity was approximately 90%, and no significant change in recovery and purity was seen between the different scales of operation.



Fig 5. Non-reduced SDS-PAGE analysis on ExcelGeI™ Gradient 8-18 of the main fractions from the scale-up experiments. The gel was stained with Coomassie.

Zinc leakage

The leakage of zinc ions was evaluated (Table 2) and show that total leakage of Zn²⁺ from IMAC Sepharose 6 Fast Flow was less than 5% at all scales. Desalting effectively removed Zn²⁺ that was mixed with the target protein. However, desalting does not remove the zinc ion (1mol/mol protein) that is anchored at the active site of r-BCA. These results demonstrate that IMAC Sepharose 6 Fast Flow medium is well adapted for process applications. Table 1. Data and results from the scale-up purification of r-BCA on IMAC Sepharose 6 Fast Flow. Comparisons of r-BCA yields and recoveries for the different runs show scalability of the application. The loading was 74% of the binding capacity of the medium.

Column	Fraction	Amount applied (mg)	Amount eluted (mg)	Recovery of protein	Recovery of r-BCA activity
HiTrap IMAC FF 1 ml	Clarified E. coli extract	12.5	_	_	_
	Eluted pool	_	11.7	94%	93%
HiTrap IMAC FF 5 ml	Clarified E. coli extract	62.4	_	_	_
	Eluted pool	_	56.1	90%	84%
HiPrep IMAC FF 16/10 (20 ml)	Clarified E. coli extract	255	_	_	_
	Eluted pool	_	235	92%	90%

Table 2. Amount of Zn^{2+} desorbed from the column at the different scales of operation, and amount of Zn^{2+} in the eluate as well as in the desalted fractions.

Sample	% desorbed Zn ²⁺ from column	Molar ratio before desalting (mol Zn²+/mol protein)	Molar ratio after desalting (mol Zn²+/mol protein)	
Eluted pool HiTrap IMAC FF 1 ml	2.9%	1.7	0.9	
Eluted pool HiTrap IMAC FF 5 ml	4.4%	2.7	1.3	
Eluted pool HiPrep IMAC FF 16/10 (20 ml)	2.7%	1.6	1.4	

Conclusions

This study demonstrates that IMAC Sepharose 6 Fast Flow is well adapted for laboratory- to process-scale purification of untagged proteins with good selectivity and recovery of the target protein. No problems where encountered in the scaleup of the capture step for purification of r-BCA from *E. coli* extract.

The elution of the target protein was conveniently performed with a simple, stepwise pH gradient resulting in a concentrated fraction upon elution. This elution method is also economically sound and environmentally friendly. For some proteins that are sensitive to exposure to low pH, elution with a linear or stepwise gradient of imidazole is a good alternative. Zn²⁺ was found to be the best metal ion for use in this application at process-scale since it is less toxic and more environmentally friendly than Ni²⁺ and Cu²⁺. The amount of Zn²⁺ that co-eluted with the target protein was very low, less than 5%. The Zn²⁺ ions that leaked from the column were easily removed from the target protein solution by a desalting step, leaving only the Zn²⁺ ion anchored at the active site of the protein.

The scale at which the chromatographic separation was performed did not have any significant effect on the selectivity, recovery, and purity of the target protein. In all instances, the recovery of enzymatic activity of the target protein was about 90%. www.gehealthcare.com/protein-purification www.gehealthcare.com

GE Healthcare Bio-Sciences AB Björkgatan 30 751 84 Uppsala Sweden BioProcess, ExcelGel, HiTrap, HiPrep, PhastGel, Sepharose, UNICORN, and ÄKTAexplorer are trademarks of GE Healthcare companies. GE, imagination at work and GE Monogram are trademarks of General Electric Company.

Coomassie is a trademark of ICI plc.

US pat 5,284,933, US pat 5,310,663, and their equivalents in other countries (assignee: Hoffmann-La Roche, Inc.) relate to the purification and preparation of fusion proteins and affinity peptides comprising at least two adjacent histidine residues (commonly known as the histidine-tag technology). Any customer that wishes to use IMAC Sepharose 6 Fast Flow for non-research/commercial applications under these patents is requested to contact F. Hoffmann-La Roche AG, Corporate licensing, attn. Dr Andreas Maurer, CH-4070 Basel, Switzerland, tel +41.61.687 2548, fax +41.61.687 2113, for the purpose of obtaining a license.

All goods and services are sold subject to the terms and conditions of sale of the company within GE Healthcare which supplies them. GE Healthcare reserves the right, subject to any regulatory and contractual approval, if required, to make changes in specifications and features shown herein, or discontinue the product described at any time without notice or obligation. Contact your local GE Healthcare representative for the most current information.

© 2006 General Electric Company – All rights reserved.

GE Healthcare Bio-Sciences AB, a General Electric Company.

GE Healthcare Europe GMBH Munzinger Strasse 5 D-79111 Freiburg, Germany

GE Healthcare UK Ltd Amersham Place Little Chalfont

Buckinghamshire, HP7 9NA, UK

GE Healthcare Bio-Sciences Corp 800 Centennial Avenue P.O. Box 1327 Piscataway, NJ 08855-1327, USA

GE Healthcare Bio-Sciences KK Sanken Bldg. 3-25-1, Hyakunincho Shinjuku-ku, Tokyo 169-0073, Japan

Asia Pacific Tel: +85 65 6 275 1830 Fax: +852 2811 5251 • Australasia Tel: + 61 2 9899 0999 Fax: +61 2 9899 7511 • Austria Tel: 01/57606-1619 Fax: 01/57606-1627 • Belgium Tel: 0800 73 888 Fax: 03 272 1637 • Canada Tel: 800 463 5800 Fax: 800 567 1008 • Central, Eost, & South East Europe Tel: +43 1 982 3826 Fax: +43 1 985 3827 • Demark Tel: 45 16 2400 Fax: 45 16 2424 + Fniland & Baltics Tel: +358 (I)9 512 39 40 Fax: +388 (I)9 512 39 439 • France Tel: 016 35 67 100 Fax: 01 69 41 96 77 • Germany Tel: 0761/4903 - 490 Fax: 501 1393 7300 • Unit Pel: 02 7322 12 • Japan Tel: +81 5331 9336 • Canada Tel: 5351 9356 Fax: 811 933 7300 • Tel: 162 33 730 • France Tel: 016 93 67 100 Fax: 01 69 41 96 77 • Germany Tel: 0761/4903 - 490 Fax: 551 13933 7300 • Unit Pel: 02 7322 12 • Japan Tel: +81 5331 9336 • Canada Tel: 501 593 6700 Fax: 551 13933 7300 • Unit Pel: 02 7322 12 • Japan Tel: +81 5331 9336 • Canada Tel: 51 13933 7303 • Tel: +71 951 233 730 • Tel: +71 951 230 637 • Sauth East Aritica Tel: +73 210 9600 693 • Netherlands Tel: 0165 580 401 • Norway Tel: 815 65 555 Fax: 815 65 666 • Portugal Tel: 21 417 7035 Fax: 21 417 7184 • Fussio & other C.1.5. & N.I.5 Tel: +7 (095) 230 637 • South East Asia Tel: 60 3 8024 2080 Fax: 800 616928 Fax: 0800 616927 • USA Tel: 800 526 5393 Fax: 877 295 8102

